Related Experiment Video
Updated: Jul 12, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Predicting HIV care costs using CD4 counts from clinical trials.
1Department of Pharmacology, University of Liverpool, UK, and Tibotec BVBA, Mechelen, Belgium. microhaart@aol.com
The American Journal of Managed Care
|September 7, 2007
Summary
New antiretroviral agents like darunavir/r may lower overall HIV care costs by increasing CD4 counts. This analysis predicts potential net savings in HIV treatment and care expenses.
Area of Science:
- Health Economics
- Pharmacoeconomics
- HIV/AIDS Research
Background:
- Antiretroviral therapy is crucial for managing HIV infection.
- Understanding the cost-effectiveness of new antiretroviral agents is vital for healthcare systems.
Purpose of the Study:
- To predict the impact of a novel antiretroviral agent on healthcare costs within the US HIV care setting.
- To assess the potential economic benefits of new antiretrovirals in managing HIV.
Main Methods:
- Combined CD4 count data from the POWER trials (darunavir/r) with US cohort data on patient care costs.
- Utilized published US antiretroviral drug prices to model healthcare costs.
- Predicted the effects of CD4 count increases on healthcare expenditures.
Main Results:
- While direct treatment costs increased slightly with darunavir/r, predicted net savings in overall HIV care costs were observed.
- Projected savings were $3613/person-year (HIV Research Network cohort) and $2836/person-year (University of Alabama cohort).
- Cost-saving predictions were limited to a 12-month period.
Conclusions:
- New antiretroviral agents that improve CD4 counts can potentially reduce overall healthcare costs for individuals with HIV.
- This analytical approach can be applied to evaluate other antiretrovirals and assess short-term budget impacts.
